Daxor Corporation Announces Filing of Form N-CSR for June 30, 2015

NEW YORK, NY -- (Marketwired) -- 08/28/15 -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR on Monday, August 31st, disclosing its schedule of portfolio holdings as of June 30, 2015. Copies of the form will be mailed to the Company's shareholders and will be available on Monday on the Company's website at http://www.daxor.com/pdfs/daxor-form-n-csr-06302015.pdf.

Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012. If the company was still reporting as a 1934 Act Company, we would have shown net income of $4,528,824 or $1.15 per share for the six months ended June 30, 2015. The Company had $21,356,338 of margin loans payable at December 31, 2014 and $7,937,912 of margin loans payable at June 30, 2015. However, since the company reports as an investment company, we are reporting a decrease in net assets for the six month period ended June 30, 2015.

At June 30, 2015, the Company had net assets of $19,530,149 or $5.01 per share versus net assets of $24,580,735 or $6.16 per share at December 31, 2014.

Net assets decreased by $(5,050,586) during the six months ended June 30, 2015. The Company had dividend income of $653,272, net realized gains from investments of $9,087,051 and net realized gains from options of $835,272. These amounts were offset by a net change in the unrealized depreciation on investments of $(7,117,879), realized losses on the sale of short positions of $(5,371,173) and a net change to the unrealized depreciation on the Company's Operating Division of $(1,885,169). The net change in the unrealized depreciation on investments of $(7,117,879) includes a charge of $(9,082,090) which is the decrease in the net fair value over cost of the Company's securities portfolio from December 31, 2014 to June 30, 2015.

The Company's investment policy is to maintain a minimum of 80% of the value of its portfolio in electric utilities. At June 30, 2015, investments in electric utilities made up 93.4% of the value of the Company's portfolio. Dividends from the Company's investments in electric utilities made up 89.4% of the Company's total dividends received for the six months ended June 30, 2015. The Company is receiving dividend income on 40 of the 48 common and preferred stocks in its investment portfolio at June 30, 2015.

The annualized portfolio turnover rate for the six months ended June 30, 2015 was 4.44% which indicates an average holding period of over 20 years for our investment portfolio. The investment approach of management is to buy stocks which it is prepared to hold for the long term.

At June 30, 2015, net fair value over cost of the Company's securities portfolio totaled $11,696,996. This was comprised of net fair value over cost of $11,925,229 and net cost over fair value of $(228,233).The Company's results from investments for the six months ended June 30, 2015 are disclosed in greater detail in the Form N-CSR which will be filed on Monday.

Michael Feldschuh, the Executive Vice-President of Daxor, stated, "Our trailing financial results reinforce our conviction that current restructuring of operations toward efficiency and profitability, which have begun in earnest in the past quarter, will be crucial to generating positive results in the coming fiscal year. We have identified important opportunities to leverage our sales efforts and will continue to pursue partnerships with entities that are promising as we add resources and rigor to this important effort."

Dr. Feldschuh, the CEO of Daxor, added the following: "We are focused on outreach to our client hospitals and members of the medical community so that understanding of the need for measuring patient's blood volume precisely to improve outcomes will become more widespread. The precise knowledge of a patient's blood volume is essential for optimally treating critically ill medical and surgical patients. Our goal is to make our method of blood volume measurement the standard of care for any patient experiencing a blood volume derangement."

The Company is continuing its stock buyback program and plans to declare and pay a dividend in December of 2015.

Contact Information:

Daxor Corporation:
Michael Feldschuh
(212)330-8500
(Executive Vice President)
[email protected]

David Frankel
212-330-8504
(Chief Financial Officer)
[email protected]

Diane Meegan
212-330-8512
(Investor Relations)
[email protected]

Source: Daxor Corp.

You May Also Be Interested In

• Hanmi Financial (HAFC) Announces 1.5M Share Buyback
• ACNB Corporation (ACNB) Reports In-Line Q1 EPS
• Esquire Financial Holdings, Inc. (ESQ) Tops Q1 EPS by 3c